{
  "report_rows": [
    {
      "kpi": "Q2 Operating EBITDA",
      "prediction": "BEAT",
      "answer": "pred ~$438M vs. cons $431.6M",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "Q2 Total Revenue",
      "prediction": "IN-LINE",
      "answer": "pred ~$1,815M vs. cons $1,810M",
      "confidence": "HIGH"
    },
    {
      "kpi": "Q2 Adj. EPS (diluted, operating)",
      "prediction": "BEAT",
      "answer": "pred ~$0.595 vs. cons $0.582",
      "confidence": "MEDIUM"
    }
  ],
  "guide_rows": [
    {
      "kpi": "FY 2026 Revenue (FY)",
      "prediction": "BETTER",
      "answer": "guide ~$7.20B vs. cons $7,018M",
      "confidence": "HIGH"
    },
    {
      "kpi": "FY 2026 Op. EBITDA (FY)",
      "prediction": "BETTER",
      "answer": "guide ~$1.755B vs. cons $1,742M",
      "confidence": "HIGH"
    },
    {
      "kpi": "FY 2026 Adj. EPS (FY)",
      "prediction": "UNCHANGED",
      "answer": "guide ~$2.375 vs. cons $2.380",
      "confidence": "HIGH"
    },
    {
      "kpi": "Q3 2026 Op. EBITDA (Q3)",
      "prediction": "BETTER",
      "answer": "guide ~$445M vs. cons ~$432M",
      "confidence": "MEDIUM"
    }
  ],
  "day1_residual_pct": 3.5,
  "day1_confidence": "MEDIUM",
  "day5_residual_pct": 5.5,
  "day5_path": "FOLLOW-THROUGH",
  "day5_rationale": "FOLLOW-THROUGH \u2014 estimate revisions should track the implied H2 raise; re-rating thesis gains another data point",
  "day5_confidence": "MEDIUM"
}